Prevalence, Correlates, and Viral Dynamics of Hepatitis Delta among Injection Drug Users | Zendy

Lauren M. Kucirka | Zendy; Homayoon Farzadegan | Zendy; Jordan Feld | Zendy; Shruti H. Mehta | Zendy; Mark A. Winters | Zendy; Jeffrey S. Glenn | Zendy; Gregory D. Kirk | Zendy; Dorry L. Segev | Zendy; Kenrad E. Nelson | Zendy; Morgan A. Marks | Zendy; Theo Heller | Zendy; Elizabeth T. Golub | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Prevalence, Correlates, and Viral Dynamics of Hepatitis Delta among Injection Drug Users

Author(s) -

Lauren M. Kucirka,

Homayoon Farzadegan,

Jordan Feld,

Shruti H. Mehta,

Mark A. Winters,

Jeffrey S. Glenn,

Gregory D. Kirk,

Dorry L. Segev,

Kenrad E. Nelson,

Morgan A. Marks,

Theo Heller,

Elizabeth T. Golub

Publication year - 2010

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/655808

Subject(s) - viremia , hepatitis d , medicine , hepatitis d virus , hepatitis b virus , hepatitis b , immunology , virology , viral load , virus , hbsag

Most hepatitis delta virus (HDV) prevalence estimates from the United States are >10 years old, and HDV has shown significant temporal variation in other populations. HDV-hepatitis B virus (HBV) dual infection progresses rapidly, has more complications, and has a different treatment regimen than HBV infection alone. Accurate estimates of prevalence and risk factors are important to help clinicians decide who to screen.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research